{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:49:40Z","timestamp":1784080180804,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["103838"],"award-info":[{"award-number":["103838"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Holt Fellowship"},{"DOI":"10.13039\/501100000286","name":"British Academy","doi-asserted-by":"crossref","award":["PF160048"],"award-info":[{"award-number":["PF160048"]}],"id":[{"id":"10.13039\/501100000286","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019544","name":"Cambridge Centre for Parkinson plus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019544","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Widespread metabolic changes are seen in neurodegenerative disease and could be used as biomarkers for diagnosis and disease monitoring. They may also reveal disease mechanisms that could be a target for therapy. In this study we looked for blood-based biomarkers in syndromes associated with frontotemporal lobar degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma metabolomic profiles were measured from 134 patients with a syndrome associated with frontotemporal lobar degeneration (behavioural variant frontotemporal dementia\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930, non fluent variant primary progressive aphasia\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926, progressive supranuclear palsy\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945, corticobasal syndrome\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200933) and 32 healthy controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-nine of 842 metabolites were significantly altered in frontotemporal lobar degeneration syndromes (after false-discovery rate correction for multiple comparisons). These were distributed across a wide range of metabolic pathways including amino acids, energy and carbohydrate, cofactor and vitamin, lipid and nucleotide pathways. The metabolomic profile supported classification between frontotemporal lobar degeneration syndromes and controls with high accuracy (88.1\u201396.6%) while classification accuracy was lower between the frontotemporal lobar degeneration syndromes (72.1\u201383.3%). One metabolic profile, comprising a range of different pathways, was consistently identified as a feature of each disease versus controls: the degree to which a patient expressed this metabolomic profile was associated with their subsequent survival (hazard ratio 0.74 [0.59\u20130.93],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0018).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The metabolic changes in FTLD are promising diagnostic and prognostic biomarkers. Further work is required to replicate these findings, examine longitudinal change, and test their utility in differentiating between FTLD syndromes that are pathologically distinct but phenotypically similar.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-020-09824-1","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T03:02:28Z","timestamp":1586487748000},"page":"2228-2238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Metabolomic changes associated with frontotemporal lobar degeneration syndromes"],"prefix":"10.1007","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-0670","authenticated-orcid":false,"given":"Alexander G.","family":"Murley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Coyle Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bowns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamen A.","family":"Tsvetanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"9824_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IRA MacKenzie","year":"2010","unstructured":"MacKenzie IRA, Neumann M, Bigio EH et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1\u20134. https:\/\/doi.org\/10.1007\/s00401-009-0612-2","journal-title":"Acta Neuropathol"},{"key":"9824_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/NDT.S38706","volume":"10","author":"L Riedl","year":"2014","unstructured":"Riedl L, Mackenzie IR, F\u00f6rstl H et al (2014) Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 10:297\u2013310. https:\/\/doi.org\/10.2147\/NDT.S38706","journal-title":"Neuropsychiatr Dis Treat"},{"key":"9824_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.0000000000003663","volume":"88","author":"PA Lewitt","year":"2017","unstructured":"Lewitt PA, Li J, Lu M et al (2017) Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology 88:862\u2013869. https:\/\/doi.org\/10.1212\/WNL.0000000000003663","journal-title":"Neurology"},{"key":"9824_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","volume":"13","author":"JB Toledo","year":"2017","unstructured":"Toledo JB, Arnold M, Kastenm\u00fcller G et al (2017) Metabolic network failures in Alzheimer\u2019s disease: a biochemical road map. Alzheimer\u2019s Dement 13:965\u2013984. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.020","journal-title":"Alzheimer\u2019s Dement"},{"key":"9824_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-016-1084-8","volume":"12","author":"A Mastrokolias","year":"2016","unstructured":"Mastrokolias A, Pool R, Mina E et al (2016) Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington\u2019s disease peripheral blood samples. Metabolomics 12:1\u201315. https:\/\/doi.org\/10.1007\/s11306-016-1084-8","journal-title":"Metabolomics"},{"key":"9824_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrneurol.2009.135","volume":"5","author":"M Eller","year":"2009","unstructured":"Eller M, Williams DR (2009) Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 5:561\u2013570. https:\/\/doi.org\/10.1038\/nrneurol.2009.135","journal-title":"Nat Rev Neurol"},{"key":"9824_CR7","doi-asserted-by":"crossref","unstructured":"Murley AG, Coyle-Gilchrist I, Rouse M et al (2019) Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. Brain (in press)","DOI":"10.1101\/19012260"},{"key":"9824_CR8","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/brain\/awr198","volume":"134","author":"JD Rohrer","year":"2011","unstructured":"Rohrer JD, Lashley T, Schott JM et al (2011) Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 134:2565\u20132581. https:\/\/doi.org\/10.1093\/brain\/awr198","journal-title":"Brain"},{"key":"9824_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1474-4422(14)70065-1","volume":"13","author":"R Ferrari","year":"2014","unstructured":"Ferrari R, Hernandez DG, Nalls MA et al (2014) Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13:686\u2013699. https:\/\/doi.org\/10.1016\/S1474-4422(14)70065-1","journal-title":"Lancet Neurol"},{"key":"9824_CR10","doi-asserted-by":"publisher","first-page":"2904.e13","DOI":"10.1016\/j.neurobiolaging.2015.06.005","volume":"36","author":"R Ferrari","year":"2015","unstructured":"Ferrari R, Grassi M, Salvi E et al (2015) A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. Neurobiol Aging 36:2904.e13\u20132904.e26. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.06.005","journal-title":"Neurobiol Aging"},{"key":"9824_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ana.24198","volume":"76","author":"FP Diekstra","year":"2014","unstructured":"Diekstra FP, Van Deerlin VM, Van Swieten JC et al (2014) C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. Ann Neurol 76:120\u2013133. https:\/\/doi.org\/10.1002\/ana.24198","journal-title":"Ann Neurol"},{"key":"9824_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ng.859","volume":"43","author":"GU H\u00f6glinger","year":"2011","unstructured":"H\u00f6glinger GU, Melhem NM, Dickson DW et al (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699\u2013705. https:\/\/doi.org\/10.1038\/ng.859","journal-title":"Nat Genet"},{"key":"9824_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1086\/513320","volume":"80","author":"S Melquist","year":"2007","unstructured":"Melquist S, Craig DW, Huentelman MJ et al (2007) Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet 80:769\u2013778. https:\/\/doi.org\/10.1086\/513320","journal-title":"Am J Hum Genet"},{"key":"9824_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/jnnp-2015-311171","volume":"86","author":"MP Laakso","year":"2015","unstructured":"Laakso MP, Jukarainen NM, Veps\u00e4l\u00e4inen J (2015) Diagnosis of dementias by high-field 1H MRS of cerebrospinal fluid. J Neurol Neurosurg Psychiatry 86:1286\u20131290. https:\/\/doi.org\/10.1136\/jnnp-2015-311171","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9824_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00104","volume":"9","author":"WS Kim","year":"2018","unstructured":"Kim WS, Jary E, Pickford R et al (2018) Lipidomics analysis of behavioral variant frontotemporal dementia: a scope for biomarker development. Front Neurol 9:1\u201311. https:\/\/doi.org\/10.3389\/fneur.2018.00104","journal-title":"Front Neurol"},{"key":"9824_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tcb.2015.08.003","volume":"25","author":"K Segawa","year":"2015","unstructured":"Segawa K, Nagata S (2015) An apoptotic \u201cEat Me\u201d signal: phosphatidylserine exposure. Trends Cell Biol 25:639\u2013650. https:\/\/doi.org\/10.1016\/j.tcb.2015.08.003","journal-title":"Trends Cell Biol"},{"key":"9824_CR17","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.celrep.2018.07.072","volume":"24","author":"J Brelstaff","year":"2018","unstructured":"Brelstaff J, Tolkovsky AM, Ghetti B et al (2018) Living neurons with tau filaments aberrantly expose phosphatidylserine and are phagocytosed by microglia. Cell Rep 24:1939\u20131948.e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.072","journal-title":"Cell Rep"},{"key":"9824_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB (2018) Neurotransmitter deficits from fronto temporal lobar degeneration. Brain 141:1263\u20131285. https:\/\/doi.org\/10.1093\/brain\/awx327","journal-title":"Brain"},{"key":"9824_CR19","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/brain\/awv133","volume":"138","author":"LE Hughes","year":"2015","unstructured":"Hughes LE, Rittman T, Regenthal R et al (2015) Improving response inhibition systems in frontotemporal dementia with citalopram. Brain 138:1961\u20131975. https:\/\/doi.org\/10.1093\/brain\/awv133","journal-title":"Brain"},{"key":"9824_CR20","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WAD.0b013e31815c3445","volume":"21","author":"K Rascovsky","year":"2007","unstructured":"Rascovsky K, Hodges JR, Kipps CM et al (2007) Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 21:S14\u2013S18. https:\/\/doi.org\/10.1097\/WAD.0b013e31815c3445","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"9824_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jamaneurol.2015.4478","volume":"73","author":"RM Ahmed","year":"2016","unstructured":"Ahmed RM, Irish M, Henning E et al (2016) Assessment of eating behavior disturbance and associated neural networks in frontotemporal dementia. JAMA Neurol 73:282\u2013290. https:\/\/doi.org\/10.1001\/jamaneurol.2015.4478","journal-title":"JAMA Neurol"},{"key":"9824_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/jnnp.2007.142133","volume":"81","author":"JJ Gonz\u00e1lez S\u00e1nchez","year":"2010","unstructured":"Gonz\u00e1lez S\u00e1nchez JJ, Nora JE, De Notaris M et al (2010) A case of malignant monophasic multiple sclerosis (Marburg\u2019s disease type) successfully treated with decompressive hemicraniectomy. J Neurol Neurosurg Psychiatry 81:1056\u20131057. https:\/\/doi.org\/10.1136\/jnnp.2007.142133","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9824_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/brain\/aww263","volume":"140","author":"RM Ahmed","year":"2017","unstructured":"Ahmed RM, Landin-Romero R, Collet TH et al (2017) Energy expenditure in frontotemporal dementia: a behavioural and imaging study. Brain 140:171\u2013183. https:\/\/doi.org\/10.1093\/brain\/aww263","journal-title":"Brain"},{"key":"9824_CR24","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456\u20132477. https:\/\/doi.org\/10.1093\/brain\/awr179","journal-title":"Brain"},{"key":"9824_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006\u20131014. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6","journal-title":"Neurology"},{"key":"9824_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"9824_CR27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1","journal-title":"Neurology"},{"key":"9824_CR28","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1021\/ac901536h","volume":"81","author":"AM Evans","year":"2009","unstructured":"Evans AM, DeHaven CD, Barrett T et al (2009) Integrated, nontargeted ultrahigh performance liquid chromatography\/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656\u20136667. https:\/\/doi.org\/10.1021\/ac901536h","journal-title":"Anal Chem"},{"key":"9824_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-7-142","volume":"7","author":"RA van den Berg","year":"2006","unstructured":"van den Berg RA, Hoefsloot HCJ, Westerhuis JA et al (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genom 7:1\u201315. https:\/\/doi.org\/10.1186\/1471-2164-7-142","journal-title":"BMC Genom"},{"key":"9824_CR30","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1093\/bioinformatics\/bti499","volume":"21","author":"AM Molinaro","year":"2005","unstructured":"Molinaro AM, Simon R, Pfeiffer RM (2005) Prediction error estimation: a comparison of resampling methods. Bioinformatics 21:3301\u20133307. https:\/\/doi.org\/10.1093\/bioinformatics\/bti499","journal-title":"Bioinformatics"},{"key":"9824_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/1961189.1961199","volume":"2","author":"CC Chang","year":"2011","unstructured":"Chang CC, Lin CJ (2011) LIBSVM: a library for support vector machines. ACM Trans Intell Syst Technol 2:1\u201327. https:\/\/doi.org\/10.1145\/1961189.1961199","journal-title":"ACM Trans Intell Syst Technol"},{"key":"9824_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2005.11.002","volume":"28","author":"J Diehl-Schmid","year":"2007","unstructured":"Diehl-Schmid J, Grimmer T, Drzezga A et al (2007) Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging 28:42\u201350. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.11.002","journal-title":"Neurobiol Aging"},{"key":"9824_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.410240308","volume":"24","author":"NL Foster","year":"1988","unstructured":"Foster NL, Gilman S, Berent S et al (1988) Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24:399\u2013406. https:\/\/doi.org\/10.1002\/ana.410240308","journal-title":"Ann Neurol"},{"key":"9824_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(02)00102-8","volume":"199","author":"K Hosaka","year":"2002","unstructured":"Hosaka K, Ishii K, Sakamoto S et al (2002) Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 199:67\u201371. https:\/\/doi.org\/10.1016\/S0022-510X(02)00102-8","journal-title":"J Neurol Sci"},{"key":"9824_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2017.00719","volume":"8","author":"JM Wilkins","year":"2018","unstructured":"Wilkins JM, Trushina E (2018) Application of metabolomics in Alzheimer\u2019s disease. Front Neurol 8:1\u201320. https:\/\/doi.org\/10.3389\/fneur.2017.00719","journal-title":"Front Neurol"},{"key":"9824_CR36","doi-asserted-by":"publisher","first-page":"eaan2788","DOI":"10.1126\/science.aan2788","volume":"359","author":"F Madeo","year":"2018","unstructured":"Madeo F, Eisenberg T, Pietrocola F, Kroemer G (2018) Spermidine in health and disease. Science (80-) 359:eaan2788. https:\/\/doi.org\/10.1126\/science.aan2788","journal-title":"Science (80-)"},{"key":"9824_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00019052-199708000-00004","volume":"10","author":"L Stefanis","year":"1997","unstructured":"Stefanis L, Burke RE, Greene LA (1997) Apoptosis in neurodegenerative disorders. Curr Opin Neurol 10:299\u2013305. https:\/\/doi.org\/10.1097\/00019052-199708000-00004","journal-title":"Curr Opin Neurol"},{"key":"9824_CR38","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.febslet.2015.05.054","volume":"589","author":"R El-Merahbi","year":"2015","unstructured":"El-Merahbi R, L\u00f6ffler M, Mayer A, Sumara G (2015) The roles of peripheral serotonin in metabolic homeostasis. FEBS Lett 589:1728\u20131734. https:\/\/doi.org\/10.1016\/j.febslet.2015.05.054","journal-title":"FEBS Lett"},{"key":"9824_CR39","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbalip.2010.05.003","volume":"1801","author":"NJ Haughey","year":"2010","unstructured":"Haughey NJ, Bandaru VVR, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer\u2019s disease neuropathogenesis. Biochim Biophys Acta Mol Cell Biol Lipids 1801:878\u2013886. https:\/\/doi.org\/10.1016\/j.bbalip.2010.05.003","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"9824_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2217\/clp.12.59","volume":"7","author":"MM Mielke","year":"2012","unstructured":"Mielke MM, Haughey NJ (2012) Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer\u2019s disease? Clin Lipidol 7:525\u2013536. https:\/\/doi.org\/10.2217\/clp.12.59","journal-title":"Clin Lipidol"},{"key":"9824_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jnnp-2013-307035","volume":"85","author":"SK Alexander","year":"2014","unstructured":"Alexander SK, Rittman T, Xuereb JH et al (2014) Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85:923\u2013927. https:\/\/doi.org\/10.1136\/jnnp-2013-307035","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9824_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mds.22946","volume":"25","author":"JD Rohrer","year":"2010","unstructured":"Rohrer JD, Paviour D, Bronstein AM et al (2010) Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis. Mov Disord 25:179\u2013188. https:\/\/doi.org\/10.1002\/mds.22946","journal-title":"Mov Disord"},{"key":"9824_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00415-009-5371-4","volume":"257","author":"JD Rohrer","year":"2010","unstructured":"Rohrer JD, Rossor MN, Warren JD (2010) Apraxia in progressive nonfluent aphasia. J Neurol 257:569\u2013574. https:\/\/doi.org\/10.1007\/s00415-009-5371-4","journal-title":"J Neurol"},{"key":"9824_CR44","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","volume":"86","author":"ITS Coyle-Gilchrist","year":"2016","unstructured":"Coyle-Gilchrist ITS, Dick KM, Patterson K et al (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86:1736\u20131743. https:\/\/doi.org\/10.1212\/WNL.0000000000002638","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09824-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-09824-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09824-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T19:25:52Z","timestamp":1617996352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-09824-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["9824"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-09824-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.02.10.20021758","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"10 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Alexander Murley, P Simon Jones, Ian Coyle Gilchrist, Lucy Bowns, Julie Wiggins and Kamen A. Tsvetanov report no disclosures. James B Rowe reports consultancy for Asceneuron and UCB; research grants from Janssen, AZ-Medimmune, Lilly; and serves as editor for Brain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study received ethical approval from the Cambridge Central Research Ethics Committee (12\/EE\/0475 and 15\/EE\/0270) and was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants with capacity gave written informed consent. The participation of those who lacked capacity was discussed with a personal consultee in accordance with the Mental Capacity Act (UK).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}